Drug Discovery Featured Articles & Applications

  1. From Path Dependency To Demonstrable Progress: FDA Modernization Act 3.0 7/23/2026

    With House passage of the FDA Modernization Act 3.0, Congress has taken another major step toward modernizing biomedical research and drug development.

  2. How AI-Powered Automation Is Redefining Pharmaceutical R&D 7/23/2026

    The autonomous lab is not a distant aspiration but a present-day competitive differentiator.

  3. Rethinking The Blueprint For Bone Regeneration: The Next Evolution In Orthobiologics 7/22/2026

    Next-generation orthobiologics could transform spinal fusion by enabling targeted bone regeneration, improving safety, and reducing reliance on traditional grafts and hardware.

  4. Pharmacogenomics In Oncology: A Pharmacokinetic Perspective 7/22/2026

    The outcome of a medical treatment is not solely determined by the efficacy of the drug itself. It also depends on the patient’s genetic makeup, biological characteristics of the disease, and individual clinical factors.

  5. From Valency To Vaccine Design: The Changing Competitive Landscape In Pneumococcal Vaccines 7/21/2026

    Pneumococcal vaccination remains one of the strongest success stories in bacterial disease prevention, but the residual burden is now posing new challenges. 

  6. Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3) 7/17/2026

    Rhogam transformed Rh disease prevention, but its plasma-derived, polyclonal biology has resisted decades of synthetic anti-D replacement efforts.

  7. Can We Cure Diabetes? 7/15/2026

    We caught up with Minutia CEO Katy Digovich to discuss engineered iPSC-derived islets intended for transplantation into the forearm, which could make a functional cure for insulin-dependent diabetes broadly accessible.

  8. Botanical Therapeutics For CNS Disorders 7/7/2026

    We caught up with Joel Stanley, founder and CEO of AJNA Biosciences, to talk about botanical drug development.

  9. Wondering If Your Org Should Purchase R&D Datasets? 7/1/2026

    Pharma/biotech companies are increasingly looking to access large-scale data sets to fill gaps in their computational biology capabilities. Be prepared for the investment.

  10. iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody 6/25/2026

    iBio has started clinical trials with a long-acting myostatin/GDF11 antibody that can make weight loss healthier and more durable for patients taking GLP-1 agonists.